<DOC>
	<DOCNO>NCT00518102</DOCNO>
	<brief_summary>The purpose study compare risk cancer patient use REGRANEX ( becaplermin ) patient similar characteristic health issue use REGRANEX ( becaplermin ) . REGRANEX ( becaplermin ) topical medication use treat non-healing neuropathic foot ulcer patient diabetes .</brief_summary>
	<brief_title>The Risk Cancer Users Regranex ( Becaplermin ) Matched Comparators ( Nonusers Regranex Becaplermin )</brief_title>
	<detailed_description>This observational retrospective study data collect medical claim database derive large national manage care organization five million member . Members enrol Medicare supplement program also include . The objective study determine incidence cancer among patient use REGRANEX ( becaplermin ) compare patient use REGRANEX ( becaplermin ) . REGRANEX ( becaplermin ) FDA-approved prescription medicine contain platelet-derived growth factor use treatment foot ulcer patient diabetes . Patients treat REGRANEX ( becaplermin ) January 1998 June 2003 identify health insurance claim database . Another group patient treat REGRANEX ( becaplermin ) similar characteristic patient treat REGRANEX ( becaplermin ) also identify time frame database . Medical record abstraction review conduct verify incident cancer identify . Follow-up study outcomes conduct date accrual termination health-plan membership December 2003 ( whichever come first ) . The date accrual date REGRANEX ( becaplermin ) exposure expose patient match unexposed comparison patient . Any incidence death cancer also identify . The primary outcome measure study incidence rate cancer kind , group organ site patient use REGRANEX ( becaplermin ) patient use REGRANEX ( becaplermin ) . A secondary objective similar comparison incidence death cancer . This observational study ; investigational drug administer .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Platelet-derived growth factor BB</mesh_term>
	<criteria>Must least 6 month continuous enrollment health plan prior Regranex initiation Any cancerrelated diagnosis identify claim data baseline ( 6 month period prior REGRANEX ( becaplermin ) initiation ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>REGRANEX ( becaplermin )</keyword>
	<keyword>Platelet-derived growth factor BB</keyword>
	<keyword>Cancer</keyword>
	<keyword>Cancer incidence</keyword>
	<keyword>Cancer mortality</keyword>
</DOC>